Title :

Endovascular treatment of cerebral sinus thrombosis due to vaccine-induced immune thrombotic thrombocytopenia

Author(s) :

Weller, Johannes [Auteur]
Krzywicka, Katarzyna [Auteur]
Van De Munckhof, Anita [Auteur]
Dorn, Franziska [Auteur]
Althaus, Katharina [Auteur]
Bode, Felix J [Auteur]
Bandettini Di Poggio, Monica [Auteur]
Buck, Brian [Auteur]
Kleinig, Timothy [Auteur]
Cordonnier, Charlotte [Auteur]
Lille Neurosciences & Cognition (LilNCog) - U 1172
Dizonno, Vanessa [Auteur]
Duan, Jiangang [Auteur]
Elkady, Ahmed [Auteur]
Chew, Beng Lim Alvin [Auteur]
Garcia-Esperon, Carlos [Auteur]
Field, Thalia S [Auteur]
Legault, Catherine [Auteur]
Morin Martin, Mar [Auteur]
Michalski, Dominik [Auteur]
Pelz, Johann [Auteur]
Schoenenberger, Silvia [Auteur]
Nagel, Simon [Auteur]
Petruzzellis, Marco [Auteur]
Raposo, Nicolas [Auteur]
Skjelland, Mona [Auteur]
Zimatore, Domenico Sergio [Auteur]
Aaron, Sanjith [Auteur]
Sanchez Van Kammen, Mayte [Auteur]
Aguiar De Sousa, Diana [Auteur]
Lindgren, Erik [Auteur]
Jood, Katarina [Auteur]
Scutelnic, Adrian [Auteur]
Heldner, Mirjam R [Auteur]
Poli, Sven [Auteur]
Arauz, Antonio [Auteur]
Conforto, Adriana B [Auteur]
Putaala, Jukka [Auteur]
Tatlisumak, Turgut [Auteur]
Arnold, Marcel [Auteur]
Coutinho, Jonathan M [Auteur]
Günther, Albrecht [Auteur]
Zimmermann, Julian [Auteur]
Ferro, José M [Auteur]

Journal title :

European Stroke Journal

Volume number :

9

Pages :

105-113

Publisher :

SAGE Publications

Publication date :

2023-09-28

ISSN :

2396-9881

English keyword(s) :

Intracranial thrombosis
thrombectomy
thrombocytopenia
vaccination
venous thrombosis
COVID-19

HAL domain(s) :

Sciences du Vivant [q-bio]

English abstract : [en]

Introduction: There is little data on the role of endovascular treatment (EVT) of cerebral venous sinus thrombosis (CVST) due to vaccine-induced immune thrombotic thrombocytopenia (VITT). Here, we describe clinical ...
Show more >Introduction: There is little data on the role of endovascular treatment (EVT) of cerebral venous sinus thrombosis (CVST) due to vaccine-induced immune thrombotic thrombocytopenia (VITT). Here, we describe clinical characteristics and outcomes of CVST-VITT patients who were treated with EVT. Patients and methods: We report data from an international registry of patients who developed CVST within 28 days of SARS-CoV-2 vaccination, reported between 29 March 2021 and 6 March 2023. VITT was defined according to the Pavord criteria. Results: EVT was performed in 18/136 (13%) patients with CVST-VITT (92% aspiration and/or stent retrieval, 8% local thrombolysis). Most common indications were extensive thrombosis and clinical or radiological deterioration. Compared to non-EVT patients, those receiving EVT had a higher median thrombus load (4.5 vs 3). Following EVT, local blood flow was improved in 83% (10/12, 95% confidence interval [CI] 54–96). One (6%) asymptomatic sinus perforation occurred. Eight (44%) patients treated with EVT also underwent decompressive surgery. Mortality was 50% (9/18, 95% CI 29–71) and 88% (8/9, 95% CI 25–66) of surviving EVT patients achieved functional independence with a modified Rankin Scale score of 0–2 at follow-up. In multivariable analysis, EVT was not associated with increased mortality (adjusted odds ratio, 0.66, 95% CI 0.16–2.58). Discussion and conclusion: We describe the largest cohort of CVST-VITT patients receiving EVT. Half of the patients receiving EVT died during hospital admission, but most survivors achieved functional independence.Show less >

Language :

Anglais

Peer reviewed article :

Oui

Audience :

Internationale

Popular science :

Non

Administrative institution(s) :

Université de Lille
Inserm
CHU Lille

Collections :

• Lille Neurosciences & Cognition (LilNCog) - U 1172

Research team(s) :

Troubles cognitifs dégénératifs et vasculaires

Submission date :

2024-01-15T22:22:49Z
2024-11-19T09:52:13Z